Over two decades, Humira, Enbrel and Remicade became three of the world's top-selling drugs, earning tens of billions of dollars between them.
While each are now OK'd for a bevy of uses, all were approved early on to treat rheumatoid arthritis, an inflammatory autoimmune condition that affects more than a million Americans.
The market for rheumatoid arthritis therapies is now one of pharma's most crowded, with new drug classes challenging the biologic trio. It's also a market in which several of the industry's fault lines converge: entry of biosimilars will challenge brands, while broader scrutiny on drug prices has put new focus on the high expense of arthritis therapies.
In this month's spotlight, BioPharma Dive explores how the rheumatoid arthritis market is changing:
Drugmakers vie to capture slice of rheumatoid arthritis market
TNF inhibitors like Humira have long held top positions. But not all patients respond and some still aren't treated with biologics — fueling further investment in the space. Read More »
5 rheumatologists discuss the evolving landscape of RA treatment
Drug pricing, JAK inhibitors and more personalized therapies are top of mind for many rheumatoid arthritis doctors. Read More »
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
The therapy lags its competitors in getting to market, but clinical data could make filgotinib stand out. How much would a late arrival hurt its prospects? Read More »
FINCH-2 data bodes well for Gilead, Galapagos JAK inhibitor
The rheumatoid arthritis study showed no patients taking filgotinib experienced deep venous thrombosis, a key concern leading up to the data readout. Read More »